Type 2 Diabetes--Restoring Glucose Homeostasis with Incretin Therapy: New Perspectives on Old Challenges CME

John L. Leahy, MD; Peter N. Weissman, MD Author Information and Disclosures

Release Date: March 17, 2008; Valid for credit through March 17, 2009

Credits Available
Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians

This activity was developed from the transcripts and slides of CME-accredited symposia titled "Type 2 Diabetes--Restoring Glucose Homeostasis with Incretin Therapy: New Perspectives on Old Challenges," which took place in Garden City, NY on November 13, 2007 and Cleveland, OH on November 14, 2007.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape, Joslin Diabetes Center or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Joslin Diabetes Center, Inc. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Joslin Diabetes Center is prohibited.
Merck & Co., Inc
Learning Objectives
Participants will be provided with clinically relevant, evidence-based information. Upon completion of this activity, participants should be able to:
  1. Explain the role of naturally occurring incretin hormones in the regulation of glucose metabolism in healthy individuals;
  2. Identify abnormalities in the development and progression of type 2 diabetes, such as insulin resistance, beta-cell dysfunction, and the role of a deficient incretin system;
  3. Design treatments targeting physiologic abnormalities using an understanding of the natural progression of these abnormalities in people with type 2 diabetes;
  4. Identify the main biological and cultural factors that may influence the development and/or course of type 2 diabetes in culturally diverse populations;
  5. Treat postprandial hyperglycemia with appropriate medical interventions;
  6. Integrate evolving treatments (including GLP-1 agonists or DPP-4 inhibitors) into current diabetes therapies.
Author Disclosures
Richard S. Beaser, MD
Disclosure: Dr. Beaser has indicated that he does not have a financial interest or other relationship with any manufacturers of any commercial products.

Enrique Caballero, MD
Disclosure: Speakers’ Bureau and Advisory Board: Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; sanofi-aventis U.S. LLC; and Takeda Pharmaceuticals North America, Inc. Advisory Board: Pfizer Inc.

Sharon Garbus
Disclosure: Sharon Garbus has indicated that she does not have a financial interest or other relationship with any manufacturers of any commercial products.

John L. Leahy, MD
Disclosure: Speakers’ Bureau and Consultant: Merck & Co., Inc. and sanofi-aventis U.S. LLC.

James E. Neighbours, MEd
Disclosure: James Neighbours has indicated that he does not have a financial interest or other relationship with any manufacturers of any commercial products.

Peter N. Weissman, MD
Disclosure: Speakers’ Bureau: GlaxoSmithKline, King Pharmaceuticals, Inc., Merck & Co., Inc. and Roche Pharmaceuticals. Grant/research support: Amgen Inc. Bristol-Myers Squibb Company, GlaxoSmithKline, Merck & Co., Inc., and Takeda Pharmaceuticals North America, Inc.
 
Joslin
The Joslin Diabetes Center, Boston, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Joslin Diabetes Center designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Provider privacy and confidentiality statement

Related Links
More Activities from Joslin

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.